147 related articles for article (PubMed ID: 10602467)
1. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
Gilmore TD
Oncogene; 1999 Nov; 18(49):6925-37. PubMed ID: 10602467
[TBL] [Abstract][Full Text] [Related]
2. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
[TBL] [Abstract][Full Text] [Related]
3. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
Mosialos G; Gilmore TD
Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
[TBL] [Abstract][Full Text] [Related]
4. The v-Rel oncoprotein increases expression from Sp1 site-containing promoters in chicken embryo fibroblasts.
Sif S; Capobianco AJ; Gilmore TD
Oncogene; 1993 Sep; 8(9):2501-9. PubMed ID: 8361761
[TBL] [Abstract][Full Text] [Related]
5. Differences in kappaB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein.
Nehyba J; Hrdlicková R; Bose HR
Oncogene; 1997 Jun; 14(24):2881-97. PubMed ID: 9205096
[TBL] [Abstract][Full Text] [Related]
6. An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation.
Fan Y; Gélinas C
Oncogene; 2007 Jun; 26(27):4038-43. PubMed ID: 17173064
[TBL] [Abstract][Full Text] [Related]
7. Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells.
Epinat JC; Dvorin EL; Gilmore TD
Oncogene; 2000 Jun; 19(28):3131-7. PubMed ID: 10918567
[TBL] [Abstract][Full Text] [Related]
8. The suppression of SH3BGRL is important for v-Rel-mediated transformation.
Majid SM; Liss AS; You M; Bose HR
Oncogene; 2006 Feb; 25(5):756-68. PubMed ID: 16186799
[TBL] [Abstract][Full Text] [Related]
9. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel.
Gilmore TD; Cormier C; Jean-Jacques J; Gapuzan ME
Oncogene; 2001 Oct; 20(48):7098-103. PubMed ID: 11704834
[TBL] [Abstract][Full Text] [Related]
10. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.
Sarkar S; Gilmore TD
Oncogene; 1993 Aug; 8(8):2245-52. PubMed ID: 8336947
[TBL] [Abstract][Full Text] [Related]
11. Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes.
Fan Y; Rayet B; Gélinas C
Oncogene; 2004 Feb; 23(5):1030-42. PubMed ID: 14647412
[TBL] [Abstract][Full Text] [Related]
12. Mutational analysis of v-rel, the oncogene of reticuloendotheliosis virus strain T.
Bhat GV; Temin HM
Oncogene; 1990 May; 5(5):625-34. PubMed ID: 2189101
[TBL] [Abstract][Full Text] [Related]
13. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
[TBL] [Abstract][Full Text] [Related]
14. Discreet mutations from c-Rel to v-Rel alter kappaB DNA recognition, IkappaBalpha binding, and dimerization: implications for v-Rel oncogenicity.
Phelps CB; Ghosh G
Oncogene; 2004 Feb; 23(6):1229-38. PubMed ID: 14961076
[TBL] [Abstract][Full Text] [Related]
15. The v-rel oncogene encodes a cell-specific transcriptional activator of certain promoters.
Gélinas C; Temin HM
Oncogene; 1988 Oct; 3(4):349-55. PubMed ID: 2856247
[TBL] [Abstract][Full Text] [Related]
16. v-Rel prevents apoptosis in transformed lymphoid cells and blocks TNFalpha-induced cell death.
Zong WX; Farrell M; Bash J; Gélinas C
Oncogene; 1997 Aug; 15(8):971-80. PubMed ID: 9285692
[TBL] [Abstract][Full Text] [Related]
17. The c-Rel transcription factor and B-cell proliferation: a deal with the devil.
Gilmore TD; Kalaitzidis D; Liang MC; Starczynowski DT
Oncogene; 2004 Mar; 23(13):2275-86. PubMed ID: 14755244
[TBL] [Abstract][Full Text] [Related]
18. Aberrant rel/nfkb genes and activity in human cancer.
Rayet B; Gélinas C
Oncogene; 1999 Nov; 18(49):6938-47. PubMed ID: 10602468
[TBL] [Abstract][Full Text] [Related]
19. Characterization of changes in gene expression associated with malignant transformation by the NF-kappaB family member, v-Rel.
Petrenko O; Ischenko I; Enrietto PJ
Oncogene; 1997 Oct; 15(14):1671-80. PubMed ID: 9349500
[TBL] [Abstract][Full Text] [Related]
20. Identification of v-Rel oncogene-induced inhibitor of apoptosis by differential display.
You M; Bose HR
Methods; 1998 Dec; 16(4):373-85. PubMed ID: 10049645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
